Use of Expedited Approval Programs for Rare Diseases
The policy is to focus development efforts on rare diseases with high unmet medical needs and accelerate new drug development by utilizing fast-track and small-scale clinical trial programs.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.